To find the highest safe dose of ziftomenib that can be combined with venetoclax and azacitidine in pediatric participants with acute leukemia that has certain…

Refractory Acute LeukemiaPediatric Relapsed

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06397027

Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors

To collect information about treatment outcomes in pediatric and adolescent patients with relapsed/refractory germ cells tumors who receive GemDMC with an ASCT.

Prospective Observational StudyGemcitabineDocetaxel+5 more

~Estimated

~$10 – $750

M.D. Anderson Cancer CenterNCT07662018